Clinical-stage company Synthetic Biologics, Inc. (NYSE American: SYN) develops therapeutics for gastrointestinal diseases. Its lead product candidates include SYN-004 that has completed Phase II clinical studies designed to degrade commonly used intravenous beta-lactam antibiotics that have been in use for years.
Recent Performance
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the recent session Company’s stock finished up 30.57% to $0.50. During the last 52-week, the stock’s best price was $0.75, while the lowest price recorded was $0.25. SYN’s current Market capitalization is 10.0 million and has a total of 11 Employees on its payroll.
Latest Highlights
- On December 22, 2020,Synthetic Biologics reported that it had been approved by the Institutional Review Board (IRB) of the Washington University School of Medicine in St. Louis (Washington University) to launch a phase 1b/2a clinical trial of SYN-004 (ribaxamase) in patients undergoing allogeneic hematopoietic cell transplantation (HCT).
- On November 23, 2020, the Company’s current listing exchange informed the Company that it was granted an extension until May 25, 2021, to attain continued listing standards as stated in the NYSE American Company Guide Sections 1003(a)(i), (ii), and (iii).
Summary
Synthetic Biologics, Inc. (NYSE American: SYN) stock skyrocketed in the premarket session as it rose 84.84% to $0.94. There seems to be no apparent reason behind this spike as the Company reported no update in the recent week. SYN’s year to date performance was 30.57%, while its weekly performance was 32.69%. This surge is attributed to nothing more than an overall buoyant update in the sector.
